Section of Cardiothoracic Surgery and Anesthesiology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Diabetes Technol Ther. 2013 Jan;15(1):26-31. doi: 10.1089/dia.2012.0169. Epub 2012 Nov 8.
Glycemic control in critically ill patients has been the topic of an interesting debate during the last decade. An accurate continuous glucose monitoring system is essential to better understand this field. This prospective study thus evaluates the accuracy and technical feasibility of a continuous glucose monitoring system using intravascular microdialysis.
Thirty patients undergoing cardiac surgery were monitored using a triple-lumen central venous catheter (Eirus TLC; Eirus Medical AB, Solna, Sweden) with an integrated microdialysis function. The catheter functions as a central venous catheter, enabling blood sampling and administration of infusions and medication while simultaneously providing continuous glucose monitoring. The patients were monitored for up to 48 h postoperatively. As reference, arterial blood gas samples were taken every hour and analyzed in a blood gas analyzer.
Six hundred seven paired samples were obtained for analysis. Using Clarke Error Grid analysis, 100% of the paired samples were in Zones A+B, and 97% were in Zone A. Mean difference (bias) was -0.12 mmol/L, and mean absolute relative difference was 5.6%. Of the paired samples, 97.5% were correct according to International Organization for Standardization criteria. Bland-Altman analysis showed bias ± limits of agreement were -0.12 ± 0.7 mmol/L. No hypoglycemic episodes were observed.
Central venous microdialysis is an accurate and reliable method for continuous blood glucose monitoring up to 48 h in patients undergoing cardiac surgery. With the microdialysis function integrated in a central venous catheter, no extra device for the continuous glucose monitoring is required. The system may be useful in critically ill patients.
在过去的十年中,危重病患者的血糖控制一直是一个有趣的争论话题。准确的连续血糖监测系统对于更好地理解这一领域至关重要。因此,本前瞻性研究评估了使用血管内微透析的连续血糖监测系统的准确性和技术可行性。
30 名接受心脏手术的患者使用带有内置微透析功能的三腔中心静脉导管(Eirus TLC;Eirus Medical AB,索纳,瑞典)进行监测。该导管作为中心静脉导管,可进行血液采样、输注和药物给药,同时提供连续血糖监测。患者术后监测长达 48 小时。作为参考,每小时采集动脉血气样本并在血气分析仪中进行分析。
共获得 607 对样本进行分析。使用 Clarke 误差网格分析,100%的配对样本位于 A+B 区,97%的配对样本位于 A 区。平均差异(偏差)为-0.12mmol/L,平均绝对相对差异为 5.6%。根据国际标准化组织标准,97.5%的配对样本是正确的。Bland-Altman 分析显示偏差±一致性界限为-0.12±0.7mmol/L。未观察到低血糖事件。
中心静脉微透析是一种准确可靠的方法,可在接受心脏手术的患者中进行长达 48 小时的连续血糖监测。微透析功能集成在中心静脉导管中,无需额外的连续血糖监测设备。该系统可能对危重病患者有用。